CClinicalTrials.gg
Not yet recruitingNCT06011135Updated Aug 25, 2023

Exploring Worry in CFS/ME

An observational study in Chronic Fatigue Syndrome, sponsored by King's College London. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-25.

Sponsored by King's College London · Observational

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Other
Time perspective
Other
Enrollment
15
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This study will be building on the findings of Kalfas et al 2022 paper exploring the prevalence of generalised worry in patients with Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) before and after Cognitive Behavioural Therapy (CBT). The research was conducted in South London and Maudsley NHS Foundation Trust's (SLaM) Persistent Physical Symptoms Research and Treatment Unit. Previous research has indicated a bidirectional relationship between fatigue and worry (Kalfas et al., 2022); the findings of this paper suggest both that many ME/CFS patients experience comorbid problematic generalised worry and that there is a positive association between severity of worry and levels of fatigue (Kalfas et al, 2022). It appears that CBT for ME/CFS indirectly treats worry, however effect sizes are small to moderate, and treatment outcomes may improve if CBT treatments incorporate strategies that target generalised worry (Kalfas et al 2022). The aims of this project are to further explore worry in this group of patients through qualitative methods.

Read the detailed description

A recent study carried out in SLaM explored how common worry is in people who have received Cognitive Behavioural Therapy (CBT) for CFS/ME. Over 70% were struggling with worry, and the more severe their level of worry was, the more severe their fatigue was likely to be. Indirectly, CBT appeared to slightly reduce how much people struggle with worry which queried: could CBT for CFS/ME be improved if we had a better understanding of worry in this context?

Worry in CFS/ME is not well understood; the present study aims to explore worry in people who have a diagnosis of CFS/ME through qualitative interviews, with the hope of gathering information to inform future treatments.

CFS/ME is a long-term condition, meaning treatments aim to manage rather than cure. It can range from a mild illness to severely disabling. National UK guidance states CBT should be offered to those living with CFS/ME. CBT treatments recognise that how our bodies function is closely linked to our thoughts, feelings, and behaviour. Research into CBT for CFS/ME shows it can improve levels of fatigue, distress, and how much people can do physically, however, in most studies improvements are small. CBT has stronger evidence for treating mental health difficulties, such as anxiety and depression. These difficulties are more common in people who have a diagnosis of CFS/ME, particularly Generalised Anxiety Disorder (GAD) which has been reported to be as high as 34%, in comparison to up to 7% of the general population. There has been little research into anxiety and how it affects fatigue, but research has identified a 'bidirectional relationship' between the two. This study is building on the finding that over 70% of people with CFS/ME could be struggling with significant worry that doesn't meet the criteria for GAD but causes distress and impacts fatigue.

02

Conditions studied

  • Chronic Fatigue Syndrome
03

In context

Fatigue Syndrome, Chronic

246 studies on the registry are indexed under Fatigue Syndrome, Chronic; 58 are open to participants now.

This study's planned enrollment of 15 is below the median of 150 across 71 observational studies indexed under Fatigue Syndrome, Chronic.

Browse Fatigue Syndrome, Chronic studies →

Lead sponsor

King's College London is the lead sponsor of 506 studies on the registry; 125 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

A purposeful sample of patients will be recruited from SLaM's Persistent Physical Symptoms Research and Treatment Unit. We are interested to collect the views of patients pre, during, and post CBT treatment to support with the secondary aim of the project which is to use the discussions to make recommendations for targeted CBT treatments. Patients will therefore be eligible to participate at any stage of their treatment following initial assessment.

Inclusion criteria

  • have a diagnosis of ME/CFS according to NICE criteria;
  • have agreed to CBT for ME/CFS following their initial assessment;
  • are/were struggling with comorbid generalised worry as determined by a score of 45 or above on the Penn State Worry Questionnaire (collected routinely with all patients referred to the service).
  • Informed consent to taking part in the study

Exclusion criteria

Exclusion Criteria:

  • Patients who have been closed to the service longer than 3 months
  • Patients with a diagnosis of long-Covid
  • Patients who are under 18
  • Patients who do not have a diagnosis of CFS/ME
  • Patients who have not agreed to CBT for CFS/ME as part of their treatment
  • Patients who score below the threshold on the PSWQ
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
15 participants (estimated)
Patient registry
No

Interventions

  • OtherNo intervention

    No intervention - qualitative study only using semi-structured interview

06

What researchers measure

Primary outcomes

  1. Exploration of how people with a diagnosis of CFS/ME experience worry

    Time frame: 31/05/2024

  2. How can this exploration of how people with a diagnosis of CFS/ME experience worry inform future research into targeted CBT interventions in the context of ME/CFS.

    Time frame: 31/05/2024

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — No individual participant data to be shared with other researchers.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06011135
Lead sponsor
King's College London
Collaborators
South London and Maudsley NHS Foundation Trust
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
Oct 1, 2023 (estimated)
Primary completion
May 31, 2024 (estimated)
Completion
May 31, 2024 (estimated)
Last update
Aug 25, 2023

Study contacts

Ellen Rhodes
Contact
ellen.rhodes@kcl.ac.uk
020 7848 0002

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion